Project Grant R01AG097434
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded The Regents of the University of California, San Francisco $460,283 through the Aging Research program (CFDA 93.866) to conduct a two-year research project from September 1, 2025 through August 31, 2027. This Project Grant supports biomedical research directed toward understanding the aging process and age-related diseases, with the funded research examining the role of reverse electron transport (RET) inhibition in...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $463,625 under the Aging Research program (CFDA 93.866) for the period September 1, 2025, through August 31, 2027. The grant supports research investigating the effects of aging on the lung adenocarcinoma tumor microenvironment, with particular focus on understanding age-related variations in immunotherapy response. The project deliverables include: (1)...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $2.59M project grant from the National Institute on Aging (Aging Research, CFDA 93.866) awarded September 15, 2025, for research examining hypothalamic pathways involved in age-related homeostatic dysregulation. The four-year project (completion date August 31, 2029) will investigate the role of supraoptic hypothalamic neurons in physiological decline with aging, with particular focus on how arginine-vasopressin (AVP)...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $701,073 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded February 15, 2026, with an ultimate completion date of December 31, 2030. The grant funds a time-sensitive prospective cohort study investigating the neurocognitive health effects of exposure to the January 2025 Los Angeles wildfires. The research will track blood-level concentrations of wildfire...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Cedars-Sinai Medical Center a Project Grant totaling $374,625 under the Aging Research program (CFDA 93.866) on September 4, 2025, with a completion date of May 31, 2030. The award supports Dr. Larissa Langhi Prata's career development and research investigating the role of senescent cells in heightened infectious disease susceptibility among elderly and chronically ill patients. The funded activities include research into...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, San Francisco a Project Grant of $182,060 under the Cardiovascular Diseases Research program (CFDA 93.837) for research investigating the role of the senescence marker P16INK4A in alveolar epithelial stem cells during injury-triggered differentiation. The award, obligated on September 30, 2025, with a completion date of November 29, 2026, supports...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the Regents of the University of California, San Francisco a Project Grant of $1,097,760 (obligated February 15, 2026) under the Cardiovascular Diseases Research program (CFDA 93.837) to support a research initiative addressing age-related pulmonary fibrosis and lung regeneration through December 31, 2032. The research program will investigate the cellular and molecular mechanisms driving idiopathic...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $256,650 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 2, 2026, with a completion date of June 30, 2028. The project, titled "ISG15 Monocytes as Precursors to SPP1 Macrophages in Scleroderma ILD," will deliver mechanistic research and biomarker discovery services focused on...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $191,700 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective July 1, 2026, through April 30, 2031. This K23 Career Development Award funds a Phase II preliminary efficacy trial of the Emotional Support in ICU (ES-ICU) intervention, designed to enhance the frequency and quality of emotional support provided by intensive care unit (ICU) teams to families of...
- Federal Grant Award Summary Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, received a $571,792 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 20, 2025, with completion targeted for May 31, 2027. The award funds research to validate APT101, a selective apelin receptor (APJ) agonist, as a therapeutic intervention for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in an aging...
Project Grant Summary Cedars-Sinai Medical Center received a $671,107 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded July 15, 2026, with a completion date of April 30, 2031. The award funds research investigating the role of P53 acetylation in driving alveolar progenitor cell senescence in progressive pulmonary fibrosis (IPF). The research employs transgenic mouse models and molecular biology techniques to elucidate the post-translational mechanisms by which P53 acetylation stabilizes the protein and promotes AT2 (alveolar type 2) cell senescence, a critical pathogenic feature of IPF. The work focuses on understanding how reduced SIRT1 deacetylase expression and increased CBP/P300 acetyltransferase activity—both features of aging—drive maladaptive P53 acetylation and progressive lung fibrosis, with implications for identifying therapeutic targets to prevent or reverse disease progression in aging populations. The research deliverables include mechanistic characterization of the P53 acetylation pathway in AT2 cell senescence, validation of SIRT1 as a protective deacetylase target, and evaluation of pharmacologic and genetic approaches to modulate P53 acetylation in fibrosis models. These findings directly advance the NIA's mission to support biomedical research aimed at understanding aging processes and age-related diseases, contributing to potential prevention and treatment strategies for IPF, a progressive interstitial lung disease predominantly affecting older adults.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $671.1k | 7/17/26 |